President Trump Signs Executive Order Directing Federal Agencies to Reschedule Cannabis to a Schedule III Drug

|Article
Lowndes

Federal cannabis policy just took its biggest step forward in decades. On Thursday, December 18, 2025, President Trump signed an executive order directing federal agencies to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. The order instructs the Attorney General and other agencies to complete the rulemaking necessary, in the “most expeditious manner.”

Under current federal law, cannabis is a Schedule I drug, alongside heroin and LSD, meaning the federal government believes there is no currently accepted medical use and a high potential for abuse.

Moving cannabis to Schedule III would place it in a less restrictive category of controlled substances. Schedule III drugs are defined as having a lower potential for abuse, accepted medical uses, and moderate dependence.

The executive order does not by itself reclassify cannabis; the formal change will only take effect after federal agencies and the Attorney General complete the process required under federal law. Most importantly, rescheduling does not legalize cannabis under federal law, it remains a controlled substance.

This executive order will have a significant impact on medical marijuana research and cannabis businesses. The change is expected to ease some restrictions on research into medical marijuana use by removing some of the barriers tied to Schedule I classification. Additionally, the rescheduling will likely allow cannabis businesses to deduct ordinary business expenses under federal tax law (Section 280E doesn’t apply to Schedule III substances the same way it does to Schedule I/II).

In summary, this executive order is a significant step toward federal cannabis reform.  

We will continue to monitor cannabis federally and share updates regarding its potential impacts on the cannabis industry. If you have questions in the meantime, please don't hesitate to contact Tara Tedrow at Tara.Tedrow@lowndes-law.com.


This article is for informational purposes only and does not provide legal advice. Please do not act or refrain from acting based on anything you read here. Please review the full disclaimer for more information. Relying on the information provided in this article or communicating with Lowndes through our website does not create an attorney/client relationship.

Subscribe to Lowndes' Insights & Events

Jump to Page

We use cookies on our website to improve functionality and collect statistical information on our website traffic. For details on how we use cookies, please see our Privacy Policy. By using this website, you agree to our Privacy Policy and Terms of Use

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. This type of cookie does not collect any personally identifiable information about you and does not track your browsing habits. You may disable necessary cookies by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies (also known as performance cookies) help us improve our website by collecting and reporting information on its usage at an aggregate level. You may disable analytical cookies by clicking on the Manage Cookies button.